| Literature DB >> 32382529 |
Wafa F S Badulla1, Mohammed Alshakka2, Mohamed Izham Mohamed Ibrahim3.
Abstract
BACKGROUND: There is a rapid deterioration in the effectiveness of antibiotics due to the global prevalence of bacterial antimicrobial resistance (AMR). AMR can cause an increase in mortality and morbidity due to treatment failures and a lack of effective therapy.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32382529 PMCID: PMC7195635 DOI: 10.1155/2020/1810290
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Sex, patient category, and laboratory distribution.
| Frequency | Percentage | |
|---|---|---|
| Gender | ||
| Male | 178 | 43.2 |
| Female | 234 | 56.8 |
| Patient category | ||
| Child | 57 | 13.8 |
| Adult | 355 | 86.2 |
| Study location | ||
| National Blood Transfusion and Research Center | 35 | 8.5 |
| Al-Medina medical laboratories | 234 | 56.8 |
| Babel Hospital | 41 | 10.0 |
| Aden German International Hospital | 102 | 24.8 |
Distribution of bacterial isolates with the specimens.
| Specimen | Bacteria |
| Total |
|---|---|---|---|
| Urine |
| 90 (60%) | 150 |
|
| 38 (25.33%) | ||
|
| 13 (8.66%) | ||
|
| 2 (1.33%) | ||
|
| 1 (0.66%) | ||
|
| 2 (1.33%) | ||
|
| 2 (1.33%) | ||
|
| 1 (0.66%) | ||
|
| 1 (0.6%) | ||
|
| |||
| Plural |
| 3 (50%) | 6 |
|
| 2 (33.33%) | ||
|
| 1 (16.67%) | ||
|
| |||
| Ear swab |
| 16 (72.72%) | 22 |
|
| 3 (13.63%) | ||
|
| 2 (9.09%) | ||
|
| 1 (4.54%) | ||
|
| |||
| Wound swab |
| 25 (49.01%) | 51 |
|
| 14 (27.45%) | ||
|
| 4 (7.84%) | ||
|
| 3 (5.88%) | ||
|
| 2 (3.92%) | ||
|
| 2 (3.92%) | ||
|
| 1 (1.96%) | ||
|
| |||
| Throat swab |
| 2 (40%) | 5 |
|
| 2 (40%) | ||
|
| 1 (20%) | ||
|
| |||
| Vaginal swab |
| 16 (42.10%) | 38 |
|
| 15 (39.47%) | ||
|
| 3 (7.89%) | ||
|
| 3 (7.89%) | ||
|
| 1 (2.63) | ||
|
| |||
| Nasal swab |
| 3 (75%) | 4 |
|
| 1 (25%) | ||
|
| |||
| Sputum |
| 3 (37.5%) | 8 |
|
| 2 (25.00%) | ||
|
| 1 (12.50%) | ||
|
| 1 (12.50%) | ||
|
| 1 (12.50%) | ||
|
| |||
| Blood |
| 13 (92.85%) | 14 |
|
| 1 (7.14%) | ||
|
| |||
| Cervical secretion |
| 2 (66.66%) | 3 |
|
| 1 (33.33%) | ||
|
| |||
| Skin specimen |
| 3 (100%) | 3 |
|
| |||
| Pus swab |
| 41 (59.42%) | 69 |
|
| 20 (28.98%) | ||
|
| 4 (5.79%) | ||
|
| 4 (5.79%) | ||
|
| |||
| Nasopharynges |
| 4 (100%) | 4 |
|
| |||
| Semen |
| 6 (66.66%) | 9 |
|
| 2 (22.22%) | ||
|
| 1 (11.11%) | ||
|
| |||
| Cerebrospinal fluid |
| 3 (75%) | 4 |
|
| 1 (25%) | ||
|
| |||
| Stool |
| 16 (88.88%) | 18 |
|
| 2 (11.11%) | ||
|
| |||
| Catheter swab |
| 1 (100%) | 1 |
|
| |||
| Eye swab |
| 1 (100%) | 1 |
|
| |||
| Tracheostomy swab |
| 1 (100%) | 1 |
|
| |||
| Rectal swab |
| 1 (100%) | 1 |
Bacterial resistance patterns to the selected antibiotics.
| Type of isolate | Antimicrobial nonsusceptibility | ||||||
| Amoxicillin with clavulanate | Ampicillin with sulbactam | Azithromycin | Cefepime | Cefotaxime | Cefoxitin | Ceftriaxone | |
|
| 5/8 (62.50) | 0/1(0) | 2/6 (33.33) | 5/7 (71.43) | 2/6 (33.33) | 1/4 (25.00) | 0/3 (0) |
|
| 71/98 (72.40) | 8/20 (40.00) | 7/23 (30.43) | 61/89 (68.54) | 76/111 (68.47) | 23/85 (27.05) | 77/114 (32.45) |
|
| 24/27 (88.88) | 4/5 (80.00) | 1/9 (11.11) | 14/24 (58.33) | 7/7 (100) | 6/8 (75.00) | 9/13 (69.23) |
|
| 10/16 (62.50) | 1/31 (3.22) | 27/85 (31.76) | 20/33 (60.60) | 14/29 (48.27) | 12/65 (18.46) | 17/33 (51.51) |
|
| 6/29 (20.68) | 1/31 (3.22) | 0/1 (0) | 2/3 (66.66) | 1/3 (33.33) | ND | 1/2 (50.00) |
|
| 1/2 (50.00) | ND | 1/2 (50.00) | 0/3 (0) | 0/4 (0) | 1/2 (50.00) | 0/2 (0) |
|
| 1/1 (100) | ND | 0/1 (0) | 1/1 (100) | 3/3 (100) | 0/1 (0) | ND |
|
| ND | ND | ND | ND | 1/1 (100) | ND | ND |
|
| ND | ND | ND | ND | 1/1 (100) | ND | 2/3 (66.66) |
|
| ND | ND | ND | 1/1 (100) | 0/1 (0) | 1/1 (100) | ND |
| Total | 118/181 (65.19) | 21/97 (21.65) | 38/127 (29.92) | 104/161 (64.60) | 104/166 (62.65) | 44/166 (26.50) | 107/172 (62.20) |
|
| |||||||
| Type of isolate | Antimicrobial nonsusceptibility | ||||||
| Ciprofloxacin | Ceftazidime | Cefuroxime | Ertapenem | Gentamycin | Levofloxacin | Sulfamethoxazole with trimethoprim | |
|
| 5/12 (41.66) | 1/3 (33.33) | 4/5 (80.0) | 1/5 (20.0) | 5/8 (62.50) | 0/1 (0) | 2/3 (66.66) |
|
| 28/103 (27.18) | 12/29 (41.38) | 19/26 (73.07) | 6/89 (93.25) | 9/23 (39.13) | 11/40 (27.5) | 57/75 (76.0) |
|
| 10/28 (35.71) | 8/17 (47.05) | 14/19 (73.68) | 3/4 (74.0) | 5/16 (31.25) | 0/13 (0) | 9/15 (60.0) |
|
| 19/95 (20.0) | 7/11 (63.63) | 15/45 (33.33) | 9/17 (52.94) | 12/45 (26.66) | 9/73 (12.32) | 49/66 (74.24) |
|
| ND | ND | 1/2 (50.0) | 1/2 (50.0) | 0/1 (0) | ND | 0/1 (0) |
|
| 0/1 (0) | ND | 1/2 (50.0) | 0/2 (0) | 0/1 (0) | 0/2 (0) | ND |
|
| 1/5 (20.0) | 1/1 (100) | 1/1 (100) | 0/1 (0) | 0/1 (0) | 1/2 (50.0) | ND |
|
| ND | ND | 0/1 (0) | ND | 1/2 (50.0) | 0/2 (0) | ND |
|
| 0/1 (0) | ND | 1/2 (50.0) | ND | ND | 0/2 (0) | ND |
|
| 0/1 | ND | ND | ND | 0/1 (0) | ND | ND |
| Total | 63/246 (25.60) | 29/61 (47.54) | 56/103 (54.36) | 20/120 (16.67) | 32/98 (32.65) | 21/135 (15.56) | 117/160 (73.13) |